Thrombotargets is an innovative drug discovery and development group of biotech companies developing new medicines based on advances in recombinant DNA and small molecule drug technologies. Thrombotargets´s programs leverage the company’s haemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.
Thrombotargets group is comprised by three companies; Thrombotargets Corporation (Durham, NC, USA.) is responsible for Drug Development and Business Managment; Thrombotargets Europe (Barcelona, Spain) for Target Identification, Lead Validation, Lead Optimization and High Througput Screening and Biotech Libraries (Girona, Spain) for engineered targeted libraries.
Thrombotargets´s strategy is to build stockholder value by discovering new leads and advancing them to clinical phases.
With a primary focus on therapeutics for Haemostasis and Thrombotic diseases, Thrombotargets´s objective is to identify, optimize and develop highly efficacious biotech and small molecule leads with low risk profiles and large market opportunities.
Thrombotargets will achieve their objectives by operating a balanced risk business strategy:
1. Invest in our own discovery and development programs and drive these through to clinical phases before partnering the candidate with pharmaceutical companies. Thrombotargets will be compensated for this innovation and effort primarily through license fees, milestones and royalties on drug sales.
2. Collaborate with the pharmaceutical industry leaders to share the investment and the rewards associated with generating market outcomes for innovative new therapies.
3. Through the in-licensing of programs at stages of development that complement and balance our existing internal portfolio, Thombotargets leverage external innovation
Thrombotargets has developed and adapted to High Throughput Screening (HTS), a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary HTS Platforms named BioPlatformScreenTM, the Thrombotargets group is creating a continuously novel and promising pipeline. Presently, two of Thrombotargets most innovative drug candidates, TH-103MH, a novel antihemorrhagic human recombinant protein to be use topically, and TT-105, a novel anticoagulant monoclonal antibody, are undergoing Preclinical trials; these programs will begin Phase I clinical trials Q4, 2007. Recently we begun a new antifibrinolytic program (TT-111 and TT-112) in collaboration with ASINEX, Rusia due to results in the explotation of our BioplatformScreen Technology.
Asinex, Moscow, Russia
Specs, Delft, Netherland
Villapharma, Murcia, Spain
Lippso, Girona, Spain
IUCT, Barcelona, Spain
Intellectual Property Status
Thrombotargets patents state protect our intellectual property and permit the commercialization of our technologies and compounds.
Board of Directors
Javier Pedreno, Chief Executive Officer and President
Luis Caveda, Chief Operating Officer
Luis Aced , Chief Financial Officer
Lina Badimon, Associated Scientific Consultant
Juan Ramon Rodriguez, R&D Director
Rosa Fernandez , Project Development Director
Ignasi Miquel, Strategic Aliances Director
Scientific Advisory Board
Lina Badimon, Cardiovascular Research Center, Barcelona, Spain
Cam Patterson, Carolina Cardiovascular Biology Center, North Carolina, US
Ira Lamster, School of Dental and oral Surgery, University of Columbia, New York, US
Juanjo Badimón, Cardiovascular Institute and Center for Cardiovascular Health, Mount Sinai School of Medicine
Javier Pedreño, Thrombotargets, Spain
Last Updated: 07-20-2007